Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Lenalidomide belongs to a group of drugs called immunomodulatory drugs (IMiD) that can modify
or regulate the functioning of the immune system. It is an FDA approved drug for people with
multiple myeloma. It is not currently approved for use in Chronic Lymphocytic Leukemia (CLL),
but it does appear effective in CLL when used alone, and is being studied for use in
combination with chemotherapy in this and other lymphomas and leukemias.
In this research study we are hoping to learn more about the effects of lenalidomide on CLL
when given in combination with bendamustine and rituximab, which is a highly effective
regimen for initial therapy of CLL/SLL. The investigators will be looking for the highest
dose of lenalidomide that can be given safely, without causing any serious or unmanageable
side effects.